Nisa Investment Advisors, LLC Reata Pharmaceuticals Inc Transaction History

Nisa Investment Advisors, LLC

$16.7 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$79.22 - $105.37 $396 - $526	-5 Reduced 0.67%	736 $75,000
Q1 2023 May 02, 2023	BUY	$30.85 - $93.17 $15,116 - $45,653	490 Added 195.22%	741 $67,000
Q4 2022 Feb 02, 2023	BUY	$22.15 - $42.11 $132 - $252	6 Added 2.45%	251 $10,000
Q3 2022 Nov 07, 2022	SELL	$19.41 - $36.49 $1,261 - $2,371	-65 Reduced 20.97%	245 $8,000
Q2 2022 Aug 03, 2022	SELL	$20.71 - $36.5 $353,706 - $623,383	-17,079 Reduced 98.22%	310 $9,000
Q1 2022 Apr 29, 2022	SELL	$24.12 - $39.6 $21,442 - $35,204	-889 Reduced 4.86%	17,389 $570,000
Q4 2021 Feb 03, 2022	BUY	$25.61 - $110.96 $423,307 - $1.83 Million	16,529 Added 945.05%	18,278 $514,000
Q3 2021 Oct 18, 2021	SELL	$100.0 - $143.02 $73,900 - $105,691	-739 Reduced 29.7%	1,749 $176,000
Q2 2021 Aug 06, 2021	SELL	$78.27 - $151.29 $33,656 - $65,054	-430 Reduced 14.74%	2,488 $352,000
Q1 2021 Apr 26, 2021	BUY	$94.25 - $132.81 $113,100 - $159,372	1,200 Added 69.85%	2,918 $291,000
Q4 2020 Jan 25, 2021	BUY	$102.03 - $184.62 $64,789 - $117,233	635 Added 58.63%	1,718 $212,000
Q3 2020 Oct 20, 2020	SELL	$93.53 - $163.34 $108,401 - $189,311	-1,159 Reduced 51.69%	1,083 $106,000
Q2 2020 Jul 27, 2020	BUY	$126.3 - $176.56 $153,959 - $215,226	1,219 Added 119.16%	2,242 $350,000
Q1 2020 Apr 17, 2020	BUY	$124.16 - $247.74 $2,483 - $4,954	20 Added 1.99%	1,023 $148,000
Q4 2019 Jan 17, 2020	SELL	$74.57 - $217.92 $31,841 - $93,051	-427 Reduced 29.86%	1,003 $205,000
Q3 2019 Oct 17, 2019	BUY	$71.26 - $95.75 $91,212 - $122,560	1,280 Added 853.33%	1,430 $115,000
Q1 2019 Apr 17, 2019	BUY	$51.9 - $101.79 $7,785 - $15,268	150 New	150 $13,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.

Account